Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study

  1. Delimpasi, S.
  2. Mateos, M.V.
  3. Auner, H.W.
  4. Gavriatopoulou, M.
  5. Dimopoulos, M.A.
  6. Quach, H.
  7. Pylypenko, H.
  8. Hájek, R.
  9. Leleu, X.
  10. Dolai, T.K.
  11. Sinha, D.K.
  12. Venner, C.P.
  13. Benjamin, R.
  14. Garg, M.K.
  15. Doronin, V.
  16. Levy, Y.
  17. Moreau, P.
  18. Chai, Y.
  19. Arazy, M.
  20. Shah, J.
  21. Shacham, S.
  22. Kauffman, M.G.
  23. Richardson, P.G.
  24. Grosicki, S.
Zeitschrift:
American Journal of Hematology

ISSN: 1096-8652,  0361-8609

Datum der Publikation: 2022

Ausgabe: 97

Nummer: 3

Seiten: E83-E86

Art: Brief

DOI: 10.1002/AJH.26434 GOOGLE SCHOLAR lock_openOpen Access editor
Datenquelle: Scopus